Loading...
XSHE
300683
Market cap475mUSD
Jul 10, Last price  
25.92CNY
1D
5.28%
1Q
-28.38%
IPO
-49.87%
Name

Wuhan Hiteck Biological Pharma Co Ltd

Chart & Performance

D1W1MN
XSHE:300683 chart
P/E
P/S
6.27
EPS
Div Yield, %
0.53%
Shrs. gr., 5y
4.20%
Rev. gr., 5y
-2.51%
Revenues
541m
-16.57%
355,992,687548,791,131679,406,628770,974,124750,258,799590,873,499620,163,188620,163,188524,123,426614,683,452614,683,451688,625,991688,625,991602,284,306648,974,123541,449,755
Net income
-231m
L+233.48%
77,654,090109,911,99783,346,513157,053,452142,389,65194,137,74763,035,06563,035,069-25,025,70027,654,22827,654,2320-14,029,606-120,822,816-69,348,656-231,265,718
CFO
-77m
L
76,821,220135,404,687159,887,188143,859,87183,076,51173,423,47963,027,543012,088,24753,033,6645,314,25722,685,841-76,537,976
Dividend
Jan 09, 20250.13 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
IPO date
Aug 08, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122020‑002019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT